Nicole Leibman,DVM, MS, DACVIM (Oncology)
Specialist in Oncology
Service Head of Oncology
Director of the Cancer Institute Department: Oncology
Dr. Nicole Leibman received her DVM from the University of Minnesota, did her internship at the Animal Medical Center, and completed her medical oncology residency at Colorado State University. She has been practicing clinical oncology for over 15 years in the New York metropolitan area. She joined AMC as a Senior Veterinarian in 2001 and has since conducted clinical trials and published results on the canine melanoma vaccine for both oral and digit tumors. Dr. Leibman has also studied the treatment of mast cell tumors in dogs and published several studies on the staging and treatment of this disease.
She is a member of Animal Cancer Investigation, which has allowed the Animal Medical Center to participate in several trials for canine lymphoma, utilizing monoclonal antibodies. She has recently completed a study looking at glutathione supplementation and absorption in dogs. She was awarded the Robert S. Brodey Memorial Award for Outstanding Clinical Science Research Project in Oncology. Dr. Leibman has ongoing clinical trials investigating immunotherapy for injection site sarcomas in cats. Currently, she is closely collaborating with Memorial Sloan Kettering Cancer Center and NYU Langone Medical Center on a project looking at the genomic analysis of canine tumors.
- Oncology Residency Program Director
- BA – University of Wisconsin-Madison, Wisconsin
- DVM – University of Minnesota, St. Paul, Minnesota
- MS – Colorado State University-Fort Collins, Colorado
Detection of carcinoma micrometastases in bone marrow of dogs and cats using conventional and cell block cytology. Taylor BE, Leibman NF, Luong R, Loar AS, Craft DM. Vet Clin Pathol. 2013 Mar;42(1):85-91. doi: 10.1111/vcp.12011. Epub 2012 Dec 31.PMID: 23278287
Veterinary Cancer Society Award in Basic Science for:Identification of matrix metalloproteinases in canine cutaneous mast cell tumors.Plasma Cell Disorders.Consultations in Feline Internal Medicine.Leibman N, Elsevier, 2009
Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Camps-Palau MA, Leibman NF, Elmslie R, Lana SE, Plaza S, McKnight JA, Risbon R, Bergman PJ.Vet Comp Oncol. 2007 Sep;5(3):156-67.
Cytological comparison of fine-needle aspirates of liver and spleen of normal dogs and of dogs with cutaneous mast cell tumours and an ultrasonographically normal appearing liver and spleen.Finora K,Leibman NF, Fettman MJ, Powers BE, Hackett TA, Withrow SJ. Vet Comp Oncol. 2006 Sep;4(3):178-83.
Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).Ettinger SN, Scase TJ, Oberthaler KT, Craft DM, McKnight JA, Leibman NF, Charney SC, Bergman PJ.J Am Vet Med Assoc. 2006 Apr 1;228(7):1053-62.
Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).Ettinger SN, Scase TJ, Oberthaler KT, Craft DM, McKnight JA, Leibman NF, Charney SC, Bergman PJ. J Am Vet Med Assoc. 2006 Apr 1;228(7):1053-62.
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD. Vaccine. 2006 May 22;24(21):4582-5. Epub 2005 Aug 24.
Correlation of histologic grading of canine mast cell tumors with Ki67/PCNA/AgNOR/c-Kit scores: 38 cases (2002-2003). Bergman PJ, Craft DM, Newman SJ, Baer K, Camps-Palau MA, McKnight JA,Leibman NF, Brenn S, Finora K, Hohenhaus AE, Bartick T, Patnaik AK, Scase T. Vet Comp Oncol. 2004 Jun;2(2):98.
Clinical Techniques in Small Animal Practice, Medicial Oncology. Leibman N, Guest editior. May 2003 Vol 18, 2.
Leibman N. Lower Respiratory Tract Neoplasia. Feline Internal Medicine Secrets2001, 69-72
Accuracy of radiography, nuclear scintigraphy, and histopathology for determining the proximal extent of distal radius osteosarcoma in dogs. Leibman NF, Kuntz CA, Steyn PF, Fettman MJ, Powers BE, Withrow SJ, Dernell WS. Vet Surg. 2001 May-Jun;30(3):240-5.
Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). Séguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ, Withrow SJ. J Am Vet Med Assoc. 2001 Apr 1;218(7):1120-3.
Identification of matrix metalloproteinases in canine cutaneous mast cell tumors.
Leibman NF, Lana SE, Hansen RA, Powers BE, Fettman MJ, Withrow SJ, Ogilvie GK. J Vet Intern Med. 2000 Nov-Dec;14(6):583-6.